Unidade de Xenética, Departamento de Anatomía Patolóxica e Ciencias Forenses, and Instituto de Ciencias Forenses, Grupo de Medicina Xenómica (GMX), Facultade de Medicina, Universidade de Santiago de Compostela, Galicia, Spain.
PLoS One. 2013 Sep 27;8(9):e73567. doi: 10.1371/journal.pone.0073567. eCollection 2013.
Mitochondrial DNA (mtDNA) variation (i.e. haplogroups) has been analyzed in regards to a number of multifactorial diseases. The statistical power of a case-control study determines the a priori probability to reject the null hypothesis of homogeneity between cases and controls.
METHODS/PRINCIPAL FINDINGS: We critically review previous approaches to the estimation of the statistical power based on the restricted scenario where the number of cases equals the number of controls, and propose a methodology that broadens procedures to more general situations. We developed statistical procedures that consider different disease scenarios, variable sample sizes in cases and controls, and variable number of haplogroups and effect sizes. The results indicate that the statistical power of a particular study can improve substantially by increasing the number of controls with respect to cases. In the opposite direction, the power decreases substantially when testing a growing number of haplogroups. We developed mitPower (http://bioinformatics.cesga.es/mitpower/), a web-based interface that implements the new statistical procedures and allows for the computation of the a priori statistical power in variable scenarios of case-control study designs, or e.g. the number of controls needed to reach fixed effect sizes.
CONCLUSIONS/SIGNIFICANCE: The present study provides with statistical procedures for the computation of statistical power in common as well as complex case-control study designs involving 2×k tables, with special application (but not exclusive) to mtDNA studies. In order to reach a wide range of researchers, we also provide a friendly web-based tool--mitPower--that can be used in both retrospective and prospective case-control disease studies.
线粒体 DNA(mtDNA)变异(即单倍群)已在许多多因素疾病方面进行了分析。病例对照研究的统计功效决定了拒绝病例和对照之间同质的零假设的先验概率。
方法/主要发现:我们批判性地回顾了以前基于病例数等于对照数的受限情况下估计统计功效的方法,并提出了一种将方法扩展到更一般情况的方法。我们开发了统计程序,考虑了不同的疾病情况、病例和对照中不同的样本大小以及不同的单倍群数量和效应大小。结果表明,通过增加对照数相对于病例数,可以大大提高特定研究的统计功效。相反,当测试越来越多的单倍群时,功率会大大降低。我们开发了 mitPower(http://bioinformatics.cesga.es/mitpower/),这是一个基于网络的界面,实现了新的统计程序,并允许在病例对照研究设计的变量情景中计算先验统计功效,或者例如达到固定效应大小所需的对照数量。
结论/意义:本研究提供了用于计算常见和复杂病例对照研究设计中统计功效的统计程序,特别是涉及 2×k 表的 mtDNA 研究。为了满足广泛的研究人员的需求,我们还提供了一个友好的基于网络的工具--mitPower--可用于回顾性和前瞻性病例对照疾病研究。